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Objective: to investigate the relationship between bypass patency, limb survival and clinical symptoms after femorodistal
bypass procedures.
Design: multicentre, prospectively planned 12-month postoperative follow-up.
Patients and methods: five hundred and seventeen patients undergoing femorodistal bypass surgery for severe ischaemia.
Clinical symptoms, bypass patency were recorded at regular intervals up to 12 months postoperatively.
Results: complete follow-up data was obtained on 498 patients (96%). Fifty-six (17%) of the 341 patients with patent
bypasses had either rest pain or ulcers or had undergone major amputation at 12 months. Of the 167 patients with an
occluded bypass, 22 patients (13%) had improved clinical symptoms and a total of 59 patients (35%) had avoided major
amputation at 12 months. The clinical outcome for patients classified preoperatively as Fontaine stage IV was significantly
worse than for those in stage III preoperatively despite similar bypass patency rates.
Conclusions: there is a fair correlation between technical and clinical outcome after femorodistal bypass surgery at 12
months, but there are significant numbers of patients with occluded bypasses who have a good clinical outcome and of
patients with patent bypasses who have a poor clinical outcome. The reporting of symptoms in addition to bypass patency
would aid the interpretation of surgical results.
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Introduction Both bypass patency and limb salvage rates are
conventionally estimated using life-table methods.1
This method effectively excludes patients who haveResults of studies to evaluate distal arterial re-
died or are otherwise lost to follow-up and estimatesconstructions are usually presented as bypass patency
the patency rate for each interval based on the patientsand limb survival. Information on further inter-
who have survived to the beginning of this intervalventions may give patency subdivided into primary,
and whose fate is known. The assumption made, thatassisted primary and secondary patency. This method
the outcome in patients who were assessed in a givenis much concerned with the technical outcome of the
interval is likely to represent the outcome in all thoseprocedures. The clinical success of the procedure is
entered into a study, has recently been challenged andusually described only in terms of limb salvage and
the need for more complete information advocated.2it is rare that long-term follow-up of clinical symptoms
To the information on patency and limb salvage isis reported. This is surprising as it is these very symp-
sometimes added mortality, but there is usually littletoms which were the reason for the surgical inter-
information on clinical outcome.vention. The interpretation of the effectiveness of a
It has previously been reported that bypass occlusionsurgical procedure would be aided by information
does not inevitably lead to amputation3 and that someon either the patient’s symptoms or quality of life
patients with chronic critical ischaemia may improvepostoperatively.
without an operation.4 A recent prospective clinical
trial of adjuvant intravenous iloprost in femorodistal
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their limbs at 12 months and the number with relief course of the resolution of symptoms was investigated
and compared with the technical success of the bypasssymptoms.5 Data from this study were investigated
retrospectively in order to find out the extent to which procedures. Patients’ symptoms were compared in
those with patent and occluded bypasses and thebypass patency and limb salvage results are sufficient
to judge the clinical outcome of these vascular surgical patients were divided according to preoperative Fon-
taine stage.procedures.
Data were analysed according to the intent-to-treat
(ITT) principle. All patients entered into the study are
Methods accounted for and percentages refer to the 517 patients
entered unless otherwise stated. Comparison of pat-
Patients were studied prospectively during a trial of ency rates in different sub-groups was performed
adjuvant pharmacotherapy in femorodistal bypass using log-rank tests to compare pairs of curves. Com-
procedures.5 Twenty-one centres included a total of parisons of continuous data in different groups of
517 patients. The protocol was approved by the ap- patients was performed using the Mann–Whitney
propriate Ethics Committees for each of the par- Rank Sum test and the Mantel–Haenszel Chi-squared
ticipating centres. test was used for comparison of categorical data at a
The patients studied were those undergoing bypass single time-point.
surgery for severe ischaemia with the proximal ana-
stomosis above the knee and the distal anastomosis
below the knee and principally to the tibioperoneal
trunk, the anterior tibial, posterior tibial or peroneal
artery. On entry into the study and prior to surgery Results
all patients were classified as having peripheral arterial
occlusive disease (PAOD) in stage III or stage IV Patients and surgical procedures
according to the Fontaine classification, with ischaemic
rest pain of at least 14 days’ duration or trophic lesions The 517 patients entered into the study consisted of
317 male and 199 women (one patient was not clas-of arterial origin or both.
Presence or absence of ulcers, gangrene, rest pain sified) with a mean age of 71 (range 30–90). Diabetes
mellitus was recorded in 36% of patients and 35%and intermittent claudication, and the use of analgesics
were all documented before surgery and at 14 days, admitted to being current smokers. PAOD pre-
operatively was classified as stage III in 34% and3 months and 12 months after surgery. During follow-
up, the Fontaine stages were recorded as follows: stage IV in 65%. Four patients were entered with only
intermittent claudication. In total 499 patients (97%)Fontaine stage I was defined as no symptoms of isch-
aemia in the relevant leg, stage II as intermittent had rest pain indicating that almost all of the patients
in stage IV had rest pain in addition to trophic lesions.claudication, stage III as ischaemic rest pain or the use
of analgesia to control rest pain and stage IV as the Four hundred and six patients (79%) were receiving
analgesia. Ulcers were present in 256 patients (50%)presence of ischaemic ulcers or gangrene with or with-
out rest pain. Bypass patency was recorded at the same and gangrene in 221 (43%) with 140 patients (27%)
having both. Mean ankle pressure (–s.d.) on entryintervals as clinical symptoms and was confirmed
by angiography or duplex ultrasound if necessary. was 56 mmHg (–41) and the mean ankle-brachial
pressure index 0.65 (–0.32). Previous myocardial andFurther surgical interventions including amputation
were recorded whenever they occurred during follow- cerebral infarctions were recorded in 23% and 11% of
patients, respectively.up.
Assessments of clinical symptoms and bypass pat- The majority of distal anastomoses were made to
anterior and posterior tibial arteries and to the peronealency for each patient were both based on the limb
operated on entry into the study. Only one re- artery. The distribution of the distal anastomoses be-
tween these three vessels and between the differentconstructed limb per patient was included. For the
purpose of comparisons with clinical outcome, bypass levels in the calf was fairly even (Table 1). Vein grafts
were used in 424 procedures (82%) and prosthetic orpatency included successfully reopened grafts (sec-
ondary patency). Bypass patency figures reflect the prosthetic-vein composite grafts in 92 (18%). Graft
material in one procedure was unclassified. Additionalnumber of patients actually alive with patency of the
original bypass at the time of assessment. Clinical bypass grafts in the same limb were performed in 24
patients during the 12 month follow-up after occlusionsuccess of the procedures was defined as a clas-
sification of PAOD in Fontaine stage I or II. The time of the initial bypass.
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Table 1. Sites of distal anastomoses.
Level of distal anastomosis (no. of patients (%))
Artery Upper Mid Lower Totals
Below knee popliteal 9 (1.8) 0 (0.0) 0 (0.0) 9 (1.8)
Tibioperoneal trunk 40 (7.7) 2 (0.4) 2 (0.4) 44 (8.5)
Anterior tibial 56 (10.8) 53 (10.3) 70 (13.5) 179 (34.6)
Posterior tibial 22 (4.3) 57 (11.0) 65 (12.6) 144 (27.9)
Peroneal 46 (8.9) 55 (10.6) 38 (7.4) 139 (26.9)
Dorsalis pedis 0 (0.0) 0 (0.0) 2 (0.4) 2 (0.4)
All vessels 173 (33.5) 167 (32.3) 177 (34.2) 517 (100.0)
Bypass patency results
Information on bypass patency up to 12 months after
surgery was obtained in 508 patients (98%). The per-
centage of patients in the study alive with an intact
limb and patent bypass at 12 months irrespective of
graft material were 45% with primary patency and
52% with secondary patency. Primary graft patencies
at 12 months for vein and prosthetic grafts were 45%
and 40%, respectively. Secondary patency was 53% in
vein grafts and 46% in prosthetic grafts.
Bypass patency in patients who were classified as
























Pre-operative 14 days 3 months 12 months
differ (p=0.91). Similar results were found for bypass
Fig. 1. Incidence of rest pain over 12 months. (F) Continuous; (D)patency with and without rest pain (p=0.71) and for
intermittent.patency with and without gangrene preoperatively
(p=0.36).
Clinical outcome
Information on clinical outcomes up to 12 months after
surgery was available on 507 patients (98%). Over the
12 months’ follow-up 103 patients (20%) underwent a
major amputation of the operated leg. A total of 93
patients (18%) died during follow-up, eight of whom
had undergone major amputation and 85 of whom
had not. Comparison of limb salvage rates in stage III
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amputation rate in stage IV patients (p=0.063). Fig. 2. Use of analgesics over 12 months. (F) Opiate; (D) non-
The number of patients with rest pain was greatly opiate.
reduced post-operatively and most of those patients
with continuing rest pain suffered only intermittently
(Fig. 1) and were not using opiate analgesics (Fig. 2). Relationship of bypass patency to clinical outcome
The incidence of trophic lesions was reduced more
slowly postoperatively than the incidence of rest pain Information on both bypass patency and clinical out-
come up to 12 months after surgery was available onand the use of analgesia, but after 12 months only 45
patients (13% of those with lesions preoperatively) still 498 patients (96%). The proportion of patients with
patent grafts at 12 months, 52%, did not differ greatlyhad trophic lesions (Fig. 3). Very few had gangrene.
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2), although over half of the patients alive and in
Fontaine stage III or IV had patent bypasses.
The majority of patients whose bypasses did not
permanently occlude were in stage I/II at 12 months
and only 5% of these patients underwent major am-
putations. In contrast, 55% of patients with an occluded
bypass went on to have a major amputation and most
of those alive without an amputation had rest pain or
ischaemic ulcers. In total, 128 patients with occluded
bypasses were alive at 12 months. In those patients
whose bypasses had occluded, duration of patency
was compared in those with a favourable and an
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those undergoing a major amputation within the 12
Fig. 3. Presence of trophic lesions over 12 months. (F) Ulcers plus months’ follow-up period (median 26 days) was sig-
gangrene; (D) gangrene; (E) ulcers. nificantly shorter than in those patients retaining their
limb (median 68 days), p=0.019. The duration of pat-
ency in patients without substantial clinical im-
provement (stage III/IV or having undergone major
amputation) at 12 months (median 42 days) was not
significantly shorter than the duration of patency in
those patient with clinical improvement (stage I/II) at
12 months (median 79 days), although there was a
similar trend, p=0.066. These differences did not in-
dicate a threshold duration of bypass patency beyond
which amputation was unlikely or clinical im-
provement was assured. Patients at risk of later oc-
clusion could also not be identified by continuing
symptoms of ischaemia. The proportion of patients
with continuing rest pain at discharge was identical
amongst those patients who later suffered an occlusion
and amongst those whose bypasses remained patent.
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operative Fontaine stage (Table 3). In the case of a
Fig. 4. Comparison of technical and clinical success in evaluable patent bypass, patients who were in stage III before
patients. (F) Graft patency; (D) relief of rest pain; (E) healing of surgery were less likely to have died (p=0.004) and,
ulcers.
if alive without a major amputation, were more likely
to be in stage I or II at 12 months (p=0.008) than those
who were in stage IV preoperatively. If the bypass
had occluded and not been reopened at 12 months,
there was no significant association of preoperative
from 46% reporting only mild or no ischaemic symp- Fontaine stage with mortality and amputation rates,
toms (Fontaine stage I or II). However, this was the but preoperative stage III patients, who were alive
case only after 12 months. At 14 days and 3 months without a major amputation, were more likely to have
there were fewer patients with improved clinical improved to stage I or II (p=0.04).
symptoms than with a patent graft (Fig. 4). This was Patients with a preoperative stage III had overall a
particularly true for those patients with trophic lesions, 60% likelihood of being alive without a major am-
in whom resolution of symptoms took longer. putation and in stage I or II at 12 months compared
Amongst patients alive at 12 months without a major to a 38% likelihood for patients with trophic lesions
amputation in the relevant leg, there was a large preoperatively. The overall difference in mortality was
measure of agreement between technical and clinical also significant, 10% in stage III and 23% in stage IV
success. Eighty-four per cent of these patients with (p=0.0004), but the difference in incidence of major
patent bypasses were in Fontaine stage I or II and 90% amputations, 18% in stage III and 22% in stage IV was
not significant (p=0.22).of all patients in stage I or II had a patent graft (Table
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Table 2. Clinical outcome of all patients at 12 months.
Patency of bypass at 12 months
or at time of death or amputation Patent (n=341) Occluded (n=167)
Clinical outcome No. of patients (%) No. of patients (%)
Stage I/II 215 (63%) 22 (13%)
Stage III/IV 40 (12%) 37 (22%)
Amputated* 16 (5%) 89 (53%)
Dead† 67 (20%) 26 (16%)
Not recorded 6 (2%) 4 (2%)
*Includes patients who were dead at 12 months, but previously amputated.
†Includes patients who had previously been amputated.
Table 3. Relationship of clinical outcome at 12 months to preoperative Fontaine stage.
Patency at 12 months or Patent (n=340) Occluded (n=167)
at amputation or death
Stage III Stage IV Stage III Stage IV
Preoperative stage: (n=116) (n=224) (n=58) (n=109)
Clinical outcome No. patients (%) No. patients (%) No. patients (%) No. patients (%)
Stage I/II 94 (81%) 121 (54%) 14 (24%) 8 (7%)
Stage III/IV 8 (7%) 32 (14%) 12 (21%) 25 (23%)
Amputated* 2 (2%) 14 (6%) 28 (48%) 61 (56%)
Dead† 10 (9%) 57 (25%) 8 (14%) 18 (17%)
Not recorded 2 (2%) 4 (2%) 2 (4%) 2 (2%)
* Includes patients who were dead at 12 months, but previously amputated.
† Includes patients who had previously been amputated.
Twenty-two patients who had suffered a bypass 21 vascular centres from six countries, shows that less
occlusion were, nonetheless, in stage I or II at 12 than half of the patients undergoing distal bypass
months. Prior to femorodistal bypass 14 (64%) of these surgery are both alive without amputation and having
patients were in stage III, five (23%) had gangrene and no symptoms or only mild symptoms of ischaemia
two (9%) had diabetes mellitus. Ten (45%) of them after 12 months. It was also found that surgical success
(five stage III preoperatively and five stage IV) had frequently does not equate to the relief of symptoms.
received a second bypass in the same leg. The large increase in ankle pressure recorded after a
Fifty-six patients with a patent bypass at 12 months successful distal reconstruction in a severely ischaemic
were still in Fontaine stage III or IV or had undergone limb8 leads to the expectation that a rapid improvement
major amputation without bypass occlusion due to a in the clinical symptoms would follow. In this study
lack of improvement in symptoms. The majority of 517 patients were followed up for 12 months after
these patients (82%) were in stage IV preoperatively femorodistal bypass procedures for chronic ischaemia.
and 36 patients (64%) had gangrene prior to surgery. Complete follow-up of both bypass patency and clin-
Twenty-seven (48%) of them had diabetes mellitus. ical outcome were obtained in 96% of cases. This is
an unusually high rate of follow-up and provided the
opportunity to investigate the extent to which patency
and limb salvage are a sufficient guide to the clinicalDiscussion
results.
The patency rates appear low compared to manyFrom reports in the vascular surgery literature, it is
other published series, but it should be borne in mindoften difficult to assess the impact of distal arterial
that the figures reported here are the absolute numbersreconstructions on the patients. It has been proposed
of patients with a patent graft, not a probability ofthat the clinical outcome should be included in studies
graft patency, and do not exclude patients who die ordealing with lower extremity ischaemia6 and ex-
undergo major amputation. This is in contrast to mostceptionally studies report clinical outcomes in detail.7
reports. The results after 12 months’ follow-up supportBypass patency and limb salvage results are often
the conclusion that many of the patients with a patentthe only data on which the success of distal arterial
reconstructions are judged. This study, performed in bypass have an improvement in their symptoms, al-
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though less than two-thirds could be classified in of the graft. This explanation is supported by the
difference in this study between the duration of pat-Fontaine stage I or II. The improvement seemed to be
relatively slight in the first 14 days after surgery. It ency in patients with favourable and unfavourable
clinical outcomes after bypass occlusion.could be expected that ischaemic ulcers and gangrene,
and wounds from associated minor amputation pro- The overall rates of major amputation and death are
in agreement with those obtained from a large vascularcedures, might require a longer healing period. That
rest pain requires a longer period to resolve completely registry10 and an earlier prospective study.11 Major
amputation in patients with a patent graft occurred inis more unexpected. A possible explanation is the
difficulty which both the surgeon and the patient may only 5%, which compares favourably with the 8%
reported in another study in a similar population.12have experienced in distinguishing between rest pain
and pain associated with trophic lesions. Almost two- Interestingly, the rate of major amputation was 11
times higher in patients with an occluded graft, butthirds of the patients with rest pain also had trophic
lesions on entry into the study. Pain from the surgical the more frequent requirement for a second major
operation within a year in those with occlusions didwound could have played a role after 14 days, though
hardly after 3 months. not lead to a greater mortality. The mortality was in
fact slightly, though not statistically, higher in thoseIn this study clinical outcome was described using
the Fontaine classification with pain, analgesic use and patients with patent bypasses.
It is documented that trophic lesions in PAOD aretrophic lesions subdivided only into a small number
of well-defined categories which could be easily ap- associated with a higher mortality.13,14 In contrast to a
previous report,12 the major amputation rate in thisplied in a multicentre study. A possible criticism is
that the definition of Fontaine stages III and IV was study was not significantly higher in patients with
lesions. However, the differences in clinical outcomebroad with all patients suffering from any pain at rest
or receiving any analgesics for the control of ischaemic were striking, despite similar patency rates in patients
with stage III and IV preoperatively. Very few stagepain being classed as stage III. It was shown even after
only 14 days that few patients were still suffering IV patients can expect to have no symptoms or only
claudication at 12 months if their bypass occludes,from continuous pain or requiring opiate analgesics.
Similarly, patients with any trophic lesion were classed although a third of those surviving may avoid major
amputation. Even if a bypass remains patent, only justas stage IV and partial healing of lesions was not
recorded. Other classifications of clinical status have over half of the stage IV patients will have a good
clinical outcome while the figure for stage III patientsbeen suggested,6,9 but these are more complicated and
were avoided since they may be subject to differing was 90%. In patients who received a second bypass it
is difficult to judge the contribution of the initial bypassinterpretations in different hospitals. Bypass patency
rates in this study include secondary patency, as this to the long-term clinical result. However, it is notable
that five of the eight patients who were in stage IVis more likely to influence the clinical outcome than
purely primary patency. preoperative and stage I or II at 12 months despite an
occluded initial bypass had received a second bypass.The results in patients whose bypasses were oc-
cluded and not reopened showed that this did not In these cases the second procedures most probably
account for some of the clinical improvement. Thisalways lead to major amputation. Almost 40% of these
patients were alive without a major amputation after serves to stress still further the difference in progress
between patients in stage III preoperatively and those1 year and 14% could still be described as being
improved. It has been stated that the purpose of a in stage IV.
This study demonstrates that there is a reasonablebypass operation in patients with critical ischaemia is
to avoid amputation and that any outcome which correlation between patency of distal arterial re-
constructions and clinical outcome in the long-term.includes an intact limb may qualify as a success.10 By
this criterion, many patients with a bypass occlusion However, with 17% of patients with patent bypass
grafts either amputated or still in Fontaine stage III orstill had a successful clinical outcome. A clinical im-
provement despite an occluded bypass does not IV after 12 months, and 35% limb survival in patients
with occluded grafts, any evaluation of new surgicalnecessarily imply that these operations were not in-
dicated. Critical ischaemia may be viewed as an acute techniques or adjuvant therapy should include an
assessment of clinical outcome in addition to patency.exacerbation of a chronic condition and a period of
improved blood supply may be sufficient to allow the An alternative approach would be the assessment of
quality of life after bypass surgery. Appropriate scaleshealing of a trophic lesion, for example, which could
explain the longer-term success despite the occlusion are being developed15 and these could also prove to
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be a useful tool in investigating the clinical outcome Denmark: (100 patients)
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